Publications by authors named "J J Calero"
This population-based study investigated the prevalence of de novo, multitype, post-coronavirus disease (COVID) pain and its associated risk factors in previously hospitalized coronavirus disease 2019 (COVID-19) survivors. The nationwide, cross-sectional study included a cohort of Danish residents previously hospitalized due to severe acute respiratory syndrome coronavirus-2 infection between March 2020 and December 2021. Demographic data, preexisting medical comorbidities, previous pain-related symptoms, medication use for pain management, pain intensity (4-point scale), and development of de novo, multitype, post-COVID pain were collected by a self-reported survey distributed via e-Boks (a secured national digital mail system used in Denmark to provide public information to residents).
View Article and Find Full Text PDFResearch-based education at the undergraduate level is ideal for fostering the training of future scientists. In an undergraduate Developmental Biology course, this learning strategy requires the availability of model species and enough research reagents, not only for technique training but also for the development of student original projects. This might be challenging in most countries, where resources are limited.
View Article and Find Full Text PDFSingle-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Breast
April 2024
Article Synopsis
- Single-agent oral vinorelbine is a recommended treatment for advanced breast cancer that has progressed after hormone therapy, with metronomic dosing potentially offering better safety and efficacy.
- A phase II trial compared metronomic administration (50 mg three times a week) with a weekly schedule (60 mg/m initially, increasing to 80 mg/m) in 163 patients, measuring disease control rate (DCR).
- Results showed DCR was 63.4% for the metronomic group and 72.8% for the weekly group, with the weekly regimen resulting in longer progression-free and overall survival but also more side effects; both schedules are viable options for treatment.
Objective: We aimed to evaluate the use of CDK4/6 inhibitors as a risk factor for medication-related osteonecrosis of the jaw (MRONJ) in a cohort of patients with metastatic breast cancer treated with denosumab.
Methods: This was a multicentre, retrospective, observational study. All patients with breast cancer treated with denosumab (January 2011-December 2022) were included.
Lymphovascular invasion, whereby tumour cells or cell clusters are identified in the lumen of lymphatic or blood vessels, is thought to be an essential step in disease dissemination. It has been established as an independent negative prognostic indicator in a range of cancers. We therefore aimed to assess the impact of lymphovascular invasion at the time of prostatectomy on oncological outcomes.
View Article and Find Full Text PDF